Demethylating agents in myeloid malignancies.

PURPOSE OF REVIEW

Two demethylating agents are approved in myelodysplastic syndromes (MDS): 5-azacitidine and 5-aza-2'-deoxycitidine (decitabine). These drugs are structurally related and induce DNA hypomethylation. Aberrant DNA methylation is associated with gene silencing. It is proposed that hypomethylating agents work by inducing reexpression of epigenetically silenced genes. Here, we provide an up-to-date summary of the clinical experience with these drugs.

RECENT FINDINGS

5-Azacitidine and decitabine were approved in the United States based on clinical responses, but no effect on survival was documented. Recent results from a phase III study have indicated that treatment of patients with higher risk MDS with 5-azacitidine results in significant improvement in overall survival. Results of a randomized survival study of decitabine should be available in 2008. Reports of combination epigenetic therapies (a hypomethylating agent with a histone deacetylase inhibitor) indicate that these have significant activity in patients with MDS/acute myelogenous leukemia. Randomized studies are testing the concept that the combinations are superior to single-agent therapy.

SUMMARY

Demethylating agents are the standard of care for patients with higher risk MDS and the only agent known to improve the natural history of MDS. Further work in new combination therapies may result in further advances in the care of patients with MDS.